Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

Two genetic subtypes of childhood B-cell acute lymphoblastic leukemia (B-ALL) have long been associated with inferior treatment outcomes: Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-ALL.

By
January 29, 2026
3 min

Roswell Park Comprehensive Cancer Center

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Children's Oncology Group (COG)

Arcadia, California
Key Differentiators
- Pediatric Oncology
- Hematology
- Clinical Trials
#2

St. Jude Children's Research Hospital

Memphis, Tennessee
Key Differentiators
- Pediatric Hematology-Oncology
- Cancer Genomics
- Immunotherapy
#3

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Boston, Massachusetts
Key Differentiators
- Pediatric Oncology
- Immunotherapy
- Targeted Therapy
#4

Roswell Park Comprehensive Cancer Center

Buffalo, New York
Key Differentiators
- Cancer Immunotherapy
- Pediatric Oncology
- Clinical Trials
#5

National Cancer Institute (NCI)

Bethesda, Maryland
Key Differentiators
- Cancer Research
- Clinical Trials
- Immunotherapy

Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

Top Institutions in Oncology

Children's Oncology Group (COG)

St. Jude Children's Research Hospital

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Roswell Park Comprehensive Cancer Center

National Cancer Institute (NCI)

Original Source(s)

Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

Related Content

High-grade astrocytoma with piloid features: a case report of comprehensive management

Management of toxicities from antibody – drug conjugates in breast cancer

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease